AGLE logo

Aeglea BioTherapeutics (AGLE) Cash From Investing

Annual CFI

$57.01 M
+$79.63 M+352.04%

December 31, 2022

Summary

Performance

1-Year Change

+352.04%

3-Year Change

+3378.21%

5-Year Change

+353.04%

15-Year Change

+353.04%

AGLE Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$57.01 M
AGLE annual cash flow from investing activities is currently at an all-time high

3-Year Low

-$22.62 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
AGLE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
AGLE next annual earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Annual CFF

$42.68 M
AGLE annual cash flow from financing activities is $42.68 million

Annual CFO

-$80.14 M
AGLE annual cash flow from operations is -$80.14 million

Annual FCF

-$80.18 M
AGLE annual free cash flow is -$80.18 million

Annual CAPEX

$38.00 K
AGLE annual capital expenditures is $38.00 thousand

Quarterly CFI

-$97.63 M
-$104.39 M-1544.25%

September 30, 2023

Summary

Performance

3-Month Change

-1544.25%

1-Year Change

-691.74%

3-Year Change

-1787.95%

5-Year Change

-7078.63%

AGLE Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$28.62 M
AGLE quarterly cash flow from investing activities is currently -441.13% below its historical high of $28.62 million

3-Year Low

-$97.63 M
AGLE quarterly cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Quarterly CFF

-$12.53 M
AGLE quarterly cash flow from financing activities is -$12.53 million

Quarterly CFO

-$34.60 M
AGLE quarterly cash flow from operations is -$34.60 million

Quarterly FCF

-$34.60 M
AGLE quarterly free cash flow is -$34.60 million

Quarterly CAPEX

-
AGLE quarterly capital expenditures value is unknown

TTM CFI

-$59.12 M
-$114.13 M-207.48%

September 30, 2023

Summary

Performance

3-Month Change

-207.48%

1-Year Change

-212.25%

3-Year Change

-128.28%

5-Year Change

-3299.71%

AGLE TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$57.01 M
AGLE TTM cash flow from investing activities is currently -203.71% below its historical high of $57.01 million

3-Year Low

-$59.12 M
AGLE TTM cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

TTM CFF

$197.46 M
AGLE TTM cash flow from financing activities is $197.46 million

TTM CFO

-$87.01 M
AGLE TTM cash flow from operations is -$87.01 million

TTM FCF

-$87.01 M
AGLE TTM free cash flow is -$87.01 million

TTM CAPEX

-
AGLE TTM capital expenditures value is unknown

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

AGLE Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+352.0%-691.7%-212.3%
3 y3 years+3378.2%-1788.0%-128.3%
5 y5 years+353.0%-7078.6%-3299.7%

AGLE Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high-139.7%-479.0%at low-203.7%at low
5 y5-yearat high-139.7%-441.1%at low-203.7%at low
alltimeall timeat high-139.7%-441.1%at low-203.7%at low

Aeglea BioTherapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2023
-
-$97.63 M(-1544.2%)
-$59.12 M(-207.5%)
Jun 2023
-
$6.76 M(-61.9%)
$55.01 M(+12.3%)
Mar 2023
-
$17.75 M(+26.8%)
$49.00 M(-14.0%)
Dec 2022
$57.01 M(-352.0%)
$14.00 M(-15.1%)
$57.01 M(+8.2%)
Sep 2022
-
$16.50 M(+2099.9%)
$52.67 M(+25.6%)
Jun 2022
-
$750.00 K(-97.1%)
$41.95 M(-781.0%)
Mar 2022
-
$25.76 M(+166.6%)
-$6.16 M(-72.8%)
Dec 2021
-$22.62 M(+197.5%)
$9.66 M(+67.3%)
-$22.62 M(+517.7%)
Sep 2021
-
$5.78 M(-112.2%)
-$3.66 M(+0.2%)
Jun 2021
-
-$47.36 M(-609.2%)
-$3.65 M(-72.0%)
Mar 2021
-
$9.30 M(-67.5%)
-$13.06 M(+71.7%)
Dec 2020
-$7.60 M(+337.3%)
$28.62 M(+394.8%)
-$7.60 M(-70.6%)
Sep 2020
-
$5.78 M(-110.2%)
-$25.90 M(+65.3%)
Jun 2020
-
-$56.76 M(-484.7%)
-$15.67 M(+1599.6%)
Mar 2020
-
$14.75 M(+42.9%)
-$922.00 K(-47.0%)
Dec 2019
-$1.74 M(-88.6%)
$10.33 M(-35.5%)
-$1.74 M(-87.8%)
Sep 2019
-
$16.01 M(-138.1%)
-$14.20 M(-50.7%)
Jun 2019
-
-$42.01 M(-401.5%)
-$28.81 M(+380.4%)
Mar 2019
-
$13.94 M(-753.7%)
-$6.00 M(-60.6%)
DateAnnualQuarterlyTTM
Dec 2018
-$15.23 M(-32.4%)
-$2.13 M(-252.4%)
-$15.23 M(+84.5%)
Sep 2018
-
$1.40 M(-107.3%)
-$8.26 M(-48.2%)
Jun 2018
-
-$19.20 M(-508.3%)
-$15.94 M(-304.8%)
Mar 2018
-
$4.70 M(-2.9%)
$7.78 M(-134.6%)
Dec 2017
-$22.53 M(+86.6%)
$4.84 M(-177.1%)
-$22.53 M(-9.2%)
Sep 2017
-
-$6.29 M(-238.9%)
-$24.81 M(-26.6%)
Jun 2017
-
$4.52 M(-117.7%)
-$33.82 M(-7.3%)
Mar 2017
-
-$25.61 M(-1100.8%)
-$36.49 M(+202.2%)
Dec 2016
-$12.08 M(+200.8%)
$2.56 M(-116.7%)
-$12.08 M(-20.3%)
Sep 2016
-
-$15.29 M(-925.9%)
-$15.14 M(+357.6%)
Jun 2016
-
$1.85 M(-255.4%)
-$3.31 M(-36.2%)
Mar 2016
-
-$1.19 M(+133.7%)
-$5.19 M(+29.2%)
Dec 2015
-$4.01 M(+1716.3%)
-$510.00 K(-85.3%)
-$4.01 M(+11.0%)
Sep 2015
-
-$3.46 M(>+9900.0%)
-$3.62 M(+1485.5%)
Jun 2015
-
-$24.00 K(+20.0%)
-$228.00 K(+9.1%)
Mar 2015
-
-$20.00 K(-82.0%)
-$209.00 K(-5.4%)
Dec 2014
-$221.00 K
-$111.00 K(+52.1%)
-$221.00 K(+100.9%)
Sep 2014
-
-$73.00 K(+1360.0%)
-$110.00 K(+197.3%)
Jun 2014
-
-$5000.00(-84.4%)
-$37.00 K(+15.6%)
Mar 2014
-
-$32.00 K
-$32.00 K

FAQ

  • What is Aeglea BioTherapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics annual CFI year-on-year change?
  • What is Aeglea BioTherapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics quarterly CFI year-on-year change?
  • What is Aeglea BioTherapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics TTM CFI year-on-year change?

What is Aeglea BioTherapeutics annual cash flow from investing activities?

The current annual CFI of AGLE is $57.01 M

What is the all time high annual CFI for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high annual cash flow from investing activities is $57.01 M

What is Aeglea BioTherapeutics annual CFI year-on-year change?

Over the past year, AGLE annual cash flow from investing activities has changed by +$79.63 M (+352.04%)

What is Aeglea BioTherapeutics quarterly cash flow from investing activities?

The current quarterly CFI of AGLE is -$97.63 M

What is the all time high quarterly CFI for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high quarterly cash flow from investing activities is $28.62 M

What is Aeglea BioTherapeutics quarterly CFI year-on-year change?

Over the past year, AGLE quarterly cash flow from investing activities has changed by -$114.13 M (-691.74%)

What is Aeglea BioTherapeutics TTM cash flow from investing activities?

The current TTM CFI of AGLE is -$59.12 M

What is the all time high TTM CFI for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high TTM cash flow from investing activities is $57.01 M

What is Aeglea BioTherapeutics TTM CFI year-on-year change?

Over the past year, AGLE TTM cash flow from investing activities has changed by -$111.79 M (-212.25%)